Recombinant Human G-CSF Plus Vincristine/Prednisolone/Intensive Asparaginase Therapy for Treatment of Refractory Acute Lymphocytic Leukemia in Childhood.
スポンサーリンク
概要
- 論文の詳細を見る
Three children with refractory acute lymphocytic leukemia received therapy with vincristine/ prednisolone/ <I>l</I>-asparaginase and recombinant human granulocyte colony-stimulating factor (G-CSF). One patient achieved complete remission and other patients achieved incomplete remission (5% or less blasts in bone marrow with abnormal peripheral and differential counts except a granulocyte count). Remission durations were short with a median of 40 days; the median survival was 137 days. One patient died of pulmonary fungal infection, but other deaths were due to relapsed leukemia. Side effects included infections, hypoalbuminemia, hypofibrinogenemia and hyperglycemia. In conclusion, the combination of vincristine/ prednisolone/ intensive <I>l</I>-asparaginase and recombinant human G-CSF had significant activity in children with refractory acute lymphocytic leukemia but the duration of remission was short. The addition of recombinant human hemopoietic growth factors to the intensive chemotherapy and the use of the combination regimen as part of front-line maintenance intensification therapy may further improve the prognosis in these patients.
- 特定非営利活動法人 日本小児血液・がん学会の論文
特定非営利活動法人 日本小児血液・がん学会 | 論文
- The Parent's Emotional Adaptation to the Children's Malignant Disease
- Side Effect of Cranial Radiation in Childhood Acute Leukemia
- Red Blood Cell Volume Distribution Width in Normal Children and in the Patients with Various Kinds of Hematological Disorders.
- Effective Conditioning of Donors for Granulocyte Transfusions with Recombinant Human Granulocyte Colony-Stimulating Factor.
- Two Infant Girls of CNS Leukemia with Chronic Subdural Hematoma